ArticleBMC cancer2026
Evaluation of TIE-2 levels in newly diagnosed and untreated multiple myeloma patients.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiogenesis plays a crucial role in the pathophysiology of multiple myeloma (MM). Tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (TIE-2) is an important regulator of angiogenesis; however, its diagnostic value in MM has not been fully clarified. This study aimed to evaluate the diagnostic significance of serum TIE-2 levels in newly diagnosed, treatment-naïve patients with MM compared with healthy individuals.
methodsIn this prospective case-control study conducted at Adana City Training and Research Hospital between September 2017 and June 2021, 38 patients diagnosed with MM according to International Myeloma Working Group (IMWG) criteria and 37 healthy volunteers with similar age/gender characteristics were included. Serum TIE-2 levels were measured by ELISA method. Data were statistically analyzed using SPSS 20.0 software.
resultsSerum TIE-2 levels were found to be significantly higher in MM patients compared to the control group (1.4 vs. 0.9 ng/ml; p < 0.001). ROC analysis demonstrated an area under the curve (AUC) of 0.756 (95% CI: 0.643-0.848; p < 0.001). At a cut-off value of > 0.99 ng/mL, the sensitivity was 89.5% and the specificity was 59.5%.
conclusionsElevated serum TIE-2 levels in newly diagnosed MM patients suggest that this marker may reflect angiogenesis-related activation associated with MM biology. However, due to its moderate specificity, TIE-2 should be considered a complementary exploratory biomarker rather than a stand-alone diagnostic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.